STOCK TITAN

Tenaya Therapeutics Inc - TNYA STOCK NEWS

Welcome to our dedicated news page for Tenaya Therapeutics (Ticker: TNYA), a resource for investors and traders seeking the latest updates and insights on Tenaya Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tenaya Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tenaya Therapeutics's position in the market.

Rhea-AI Summary
Tenaya Therapeutics, Inc. (TNYA) reports successful advancements in genetic medicines for heart disease, with key milestones achieved in 2023. The company anticipates releasing initial data from the ongoing MyPeak-1 Phase 1b trial of TN-201 for MYBPC3-associated HCM in the second half of 2024. Additionally, Tenaya is on track to dose the first patient in the RIDGE-1 Phase 1b trial of TN-401 for PKP2-associated ARVC in the same period. The recent financing raised $47 million in net proceeds, extending the cash runway into the second half of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.02%
Tags
-
Rhea-AI Summary
Tenaya Therapeutics Announces Positive Preclinical Results for TN-401 Gene Therapy in Treating ARVC, Aiming to Address Underlying Genetic Cause of Disease
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.12%
Tags
-
Rhea-AI Summary
Tenaya Therapeutics, Inc. (TNYA) to participate in TD Cowen's 44th Annual Health Care Conference and Leerink Partners Global Biopharma Conference 2024. The company aims to develop therapies for heart disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
conferences
Rhea-AI Summary
Tenaya Therapeutics, Inc. announced the publication of preclinical research on small molecule HDAC6 inhibitors for treating Heart Failure with preserved ejection fraction (HFpEF) in Nature Communications. The research showed successful reversal of HFpEF biologic hallmarks, systemic benefits, and potential for combination therapy with SGLT2 inhibitors. The company's Phase 1 trial demonstrated promising safety and efficacy results, supporting the therapeutic potential of HDAC6 inhibitors for HFpEF patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9%
Tags
none
-
Rhea-AI Summary
Tenaya Therapeutics, Inc. announced the pricing of its underwritten offering of 8,888,890 shares of its common stock at an offering price of $4.50 per share, expecting to receive total gross proceeds of approximately $50 million. The deal included participation from new and existing investors, with the offering expected to close on or before February 11, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.06%
Tags
none
-
Rhea-AI Summary
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) announced that CEO Faraz Ali will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024, to discuss the company's mission to discover, develop, and deliver potentially curative therapies for heart disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.28%
Tags
conferences
Rhea-AI Summary
Tenaya Therapeutics, Inc. (TNYA) CEO Faraz Ali to participate in 35th Annual Piper Sandler Healthcare Conference. Webcast available on company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
conferences
-
Rhea-AI Summary
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) commenced patient dosing in the MyPeak-1 Phase 1b Trial of TN-201 for MYBPC3-Associated Hypertrophic Cardiomyopathy, presented positive Phase 1 data for TN-301 for Heart Failure with Preserved Ejection Fraction, and received FDA clearance for TN-401 for PKP2-Associated ARVC. The company also reported financial results and provided a corporate update for the third quarter ended September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.57%
Tags
-
Rhea-AI Summary
Tenaya Therapeutics has received FDA clearance to begin clinical testing of TN-401, an investigational gene therapy product candidate for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC). TN-401 aims to address the underlying cause of ARVC by delivering a fully functional PKP2 gene to restore normal PKP2 protein levels. The company plans to initiate the RIDGE-1 Phase 1b clinical trial to assess the safety, tolerability, and clinical efficacy of TN-401.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.67%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
Tenaya Therapeutics Inc

Nasdaq:TNYA

TNYA Rankings

TNYA Stock Data

350.18M
42.73M
1.53%
77.18%
3.93%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
South San Francisco

About TNYA

tenaya therapeutics is a privately-held biopharmaceutical company backed by the column group. the company was founded in 2016 by world-leading scientists from the gladstone institute’s cardiovascular division and the university of texas southwestern medical center. tenaya is dedicated to addressing heart failure through multipronged efforts that target the fundamental cellular pathologies present in diseased cardiac muscle and that leverage cutting-edge research in cardiac development and regeneration. tenaya has a lead gene therapy program focused on in vivo reprogramming of cardiac fibroblasts to cardiomyocytes to regenerate heart tissue, and additional programs focused on cardiomyopathies.